Monocytes and Prostate Cancer Cells: The Role of Interleukin 13
Author Information
Author(s): Z Culig, A Hobisch, M Herold, A Hittmair, M Thumher, IE Eder, MV Cronauer, C Rieser, R Ramoner, G Bartsch, H Klocker, G Konwalinka
Primary Institution: University of Innsbruck
Hypothesis
Do peripheral blood monocytes influence the growth and secretion in androgen-responsive prostate cancer cells?
Conclusion
Monocyte-derived interleukin 13 inhibits the proliferation of androgen-responsive prostate tumor cells and reduces androgen receptor and prostate-specific antigen levels.
Supporting Evidence
- Conditioned medium from monocytes reduced proliferation in a dose-dependent manner.
- AR protein decreased by 70% and PSA levels were reduced by approximately 80% after treatment with MCM.
- The effects of MCM were abolished by pretreatment with a neutralizing anti-IL-13 antibody.
Takeaway
Monocytes can help slow down prostate cancer cells by releasing a substance called interleukin 13, which makes the cancer cells grow less and produce less of a specific protein.
Methodology
LNCaP cells were treated with monocyte-conditioned medium to assess proliferation and secretion of prostate-specific antigen.
Limitations
The study was limited to in vitro experiments and did not explore in vivo effects.
Participant Demographics
Healthy volunteers provided peripheral blood for monocyte extraction.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website